Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia
- 27 February 2009
- journal article
- research article
- Published by Wiley in Proteomics
- Vol. 9 (5) , 1197-1206
- https://doi.org/10.1002/pmic.200800333
Abstract
The in vitro evaluation of histones and their PTMs has drawn substantial interest in the development of epigenetic therapies. The differential expression of histone isoforms may serve as a potential marker in the classification of diseases affected by chromatin abnormalities. In this study, protein profiling by LC and MS was used to explore differences in histone composition in primary chronic lymphocytic leukemia (CLL) cells. Extensive method validations were performed to determine the experimental variances that would impact histone relative abundance. The resulting data demonstrated that the proposed methodology was suitable for the analysis of histone profiles. In 4 normal individuals and 40 CLL patients, a significant decrease in the relative abundance of histone H2A variants (H2AFL and H2AFA/M*) was observed in primary CLL cells as compared to normal B cells. Protein identities were determined using high mass accuracy MS and shotgun proteomics.Keywords
This publication has 37 references indexed in Scilit:
- Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometryAnalytical Biochemistry, 2007
- Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997Journal of Clinical Oncology, 2007
- Liquid chromatography mass spectrometry profiling of histonesJournal of Chromatography B, 2007
- Histone H4 N-Terminal Acetylation in Kasumi-1 Cells Treated with Depsipeptide Determined by Acetic Acid−Urea Polyacrylamide Gel Electrophoresis, Amino Acid Coded Mass Tagging, and Mass SpectrometryJournal of Proteome Research, 2006
- Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaBlood, 2006
- DNA methyltransferases control telomere length and telomere recombination in mammalian cellsNature Cell Biology, 2006
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011Blood, 2005
- Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemiaBlood, 2002
- Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized TrialsJNCI Journal of the National Cancer Institute, 1999